Avenanthramides and avenacosides as biomarkers of oat intake: a pharmacokinetic study of solid and liquid oat consumption under single and repeated dose conditions

Saved in:
Bibliographic Details
Title: Avenanthramides and avenacosides as biomarkers of oat intake: a pharmacokinetic study of solid and liquid oat consumption under single and repeated dose conditions
Authors: Armeni, Marina, 1990, Cardilin, Tim, 1989, Fristedt, Rikard, 1978, Karlsson, Therese, 1979, Jenkins, Caroline Orfila, Nordin, Elise, 1985, Qin, Panpan, Jirstrand, Mats, 1968, Kristiansen, Karsten, Savolainen, Otto, 1982, Landberg, Rikard, 1981
Source: Nutrition Journal. 24(1)
Subject Terms: Pharmacokinetic parameter, Avenacosides, Biomarkers of oat intake, Prediction model, Avenanthramides
Description: Background: Avenanthramides (AVAs) and Avenacosides (AVEs) are unique to oats (Avena Sativa) and may serve as biomarkers of oat intake. However, information regarding their validity as food intake biomarkers is missing. We aimed to investigate critical validation parameters such as half-lives, dose-response, matrix effects, relative bioavailability under single dose, and in relation to the abundance of Feacalibacterium prausnitzii, and under repeated dosing, to understand the potential applications of AVAs and AVEs as biomarkers of oat intake. Methods: Twenty-one healthy participants consumed two oat products (solid and liquid) in a non-blinded randomized crossover study for the pharmacokinetics (PK) assessment of multiple AVAs (2p, 2c,2f, 2fd and 2pd) and AVEs (A and B). At phase I, postprandial data were collected after a single dose of either product. At phase II, fasting sample was drawn after a 4-days repeated dose setup. The postprandial data were used in a compartmental PK model and the PK parameters were consequently utilized to predict individual plasma concentrations, which were compared with the data of the second phase of the study. Results: Tmax values were shorter in liquid compared to solid form for AVAs (0.7–1.6 h and 1.1–2.3 h, respectively). In liquid, T1/2 were 1.3 h (AVA 2p and AVA 2fd), 3.2 h (AVA 2f, AVE A) and 2.5 h (AVA 2pd, AVE B). In solid form, T1/2 were shorter for AVAs (1.4–2.6 h) compared to AVEs (3.3–3.8 h). The normalized area under the curve (AUCnorm) was greater for liquid than solid form for AVA2p, 2f and AVE-A [0.7–27 nM∙h (liquid), 0.4–20.1 (solid)] while for AVE-B AUCnorm were comparable [1.8 ± 0.2 nM∙h (liquid),2.1 ± 0.3 nM∙h (solid)]. A pharmakcokinetic prediction model described 75% of the experimental plasma-concentration data from phase II, with good agreement (bias: -0.145 nM). Conclusions: AVAs are promising candidates as compliance biomarkers of oat intake in intervention studies regardless of the tested food matrices. However, due to their short elimination half-lives, their applicability in nutritional epidemiology where long-term habitual intake is of main interest, seems restricted. Clinical trial number: This study was registered at clinicaltrials.gov with the clinical trial number: NCT05511077, on August 22nd, 2022.
File Description: electronic
Access URL: https://research.chalmers.se/publication/548439
https://research.chalmers.se/publication/548439/file/548439_Fulltext.pdf
Database: SwePub
FullText Text:
  Availability: 0
CustomLinks:
  – Url: https://research.chalmers.se/publication/548439#
    Name: EDS - SwePub (s4221598)
    Category: fullText
    Text: View record in SwePub
  – Url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&db=pmc&term=1475-2891[TA]+AND+[PG]+AND+2025[PDAT]
    Name: FREE - PubMed Central (ISSN based link)
    Category: fullText
    Text: Full Text
    Icon: https://imageserver.ebscohost.com/NetImages/iconPdf.gif
    MouseOverText: Check this PubMed for the article full text.
  – Url: https://resolver.ebscohost.com/openurl?sid=EBSCO:edsswe&genre=article&issn=14752891&ISBN=&volume=24&issue=1&date=20250101&spage=&pages=&title=Nutrition Journal&atitle=Avenanthramides%20and%20avenacosides%20as%20biomarkers%20of%20oat%20intake%3A%20a%20pharmacokinetic%20study%20of%20solid%20and%20liquid%20oat%20consumption%20under%20single%20and%20repeated%20dose%20conditions&aulast=Armeni%2C%20Marina&id=DOI:10.1186/s12937-025-01204-7
    Name: Full Text Finder
    Category: fullText
    Text: Full Text Finder
    Icon: https://imageserver.ebscohost.com/branding/images/FTF.gif
    MouseOverText: Full Text Finder
  – Url: https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=EBSCO&SrcAuth=EBSCO&DestApp=WOS&ServiceName=TransferToWoS&DestLinkType=GeneralSearchSummary&Func=Links&author=Armeni%20M
    Name: ISI
    Category: fullText
    Text: Nájsť tento článok vo Web of Science
    Icon: https://imagesrvr.epnet.com/ls/20docs.gif
    MouseOverText: Nájsť tento článok vo Web of Science
Header DbId: edsswe
DbLabel: SwePub
An: edsswe.oai.research.chalmers.se.190230cd.9962.4b0b.84ef.8491654e18c0
RelevancyScore: 1065
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 1064.736328125
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Avenanthramides and avenacosides as biomarkers of oat intake: a pharmacokinetic study of solid and liquid oat consumption under single and repeated dose conditions
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Armeni%2C+Marina%22">Armeni, Marina</searchLink>, 1990<br /><searchLink fieldCode="AR" term="%22Cardilin%2C+Tim%22">Cardilin, Tim</searchLink>, 1989<br /><searchLink fieldCode="AR" term="%22Fristedt%2C+Rikard%22">Fristedt, Rikard</searchLink>, 1978<br /><searchLink fieldCode="AR" term="%22Karlsson%2C+Therese%22">Karlsson, Therese</searchLink>, 1979<br /><searchLink fieldCode="AR" term="%22Jenkins%2C+Caroline+Orfila%22">Jenkins, Caroline Orfila</searchLink><br /><searchLink fieldCode="AR" term="%22Nordin%2C+Elise%22">Nordin, Elise</searchLink>, 1985<br /><searchLink fieldCode="AR" term="%22Qin%2C+Panpan%22">Qin, Panpan</searchLink><br /><searchLink fieldCode="AR" term="%22Jirstrand%2C+Mats%22">Jirstrand, Mats</searchLink>, 1968<br /><searchLink fieldCode="AR" term="%22Kristiansen%2C+Karsten%22">Kristiansen, Karsten</searchLink><br /><searchLink fieldCode="AR" term="%22Savolainen%2C+Otto%22">Savolainen, Otto</searchLink>, 1982<br /><searchLink fieldCode="AR" term="%22Landberg%2C+Rikard%22">Landberg, Rikard</searchLink>, 1981
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <i>Nutrition Journal</i>. 24(1)
– Name: Subject
  Label: Subject Terms
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Pharmacokinetic+parameter%22">Pharmacokinetic parameter</searchLink><br /><searchLink fieldCode="DE" term="%22Avenacosides%22">Avenacosides</searchLink><br /><searchLink fieldCode="DE" term="%22Biomarkers+of+oat+intake%22">Biomarkers of oat intake</searchLink><br /><searchLink fieldCode="DE" term="%22Prediction+model%22">Prediction model</searchLink><br /><searchLink fieldCode="DE" term="%22Avenanthramides%22">Avenanthramides</searchLink>
– Name: Abstract
  Label: Description
  Group: Ab
  Data: Background: Avenanthramides (AVAs) and Avenacosides (AVEs) are unique to oats (Avena Sativa) and may serve as biomarkers of oat intake. However, information regarding their validity as food intake biomarkers is missing. We aimed to investigate critical validation parameters such as half-lives, dose-response, matrix effects, relative bioavailability under single dose, and in relation to the abundance of Feacalibacterium prausnitzii, and under repeated dosing, to understand the potential applications of AVAs and AVEs as biomarkers of oat intake. Methods: Twenty-one healthy participants consumed two oat products (solid and liquid) in a non-blinded randomized crossover study for the pharmacokinetics (PK) assessment of multiple AVAs (2p, 2c,2f, 2fd and 2pd) and AVEs (A and B). At phase I, postprandial data were collected after a single dose of either product. At phase II, fasting sample was drawn after a 4-days repeated dose setup. The postprandial data were used in a compartmental PK model and the PK parameters were consequently utilized to predict individual plasma concentrations, which were compared with the data of the second phase of the study. Results: Tmax values were shorter in liquid compared to solid form for AVAs (0.7–1.6 h and 1.1–2.3 h, respectively). In liquid, T1/2 were 1.3 h (AVA 2p and AVA 2fd), 3.2 h (AVA 2f, AVE A) and 2.5 h (AVA 2pd, AVE B). In solid form, T1/2 were shorter for AVAs (1.4–2.6 h) compared to AVEs (3.3–3.8 h). The normalized area under the curve (AUCnorm) was greater for liquid than solid form for AVA2p, 2f and AVE-A [0.7–27 nM∙h (liquid), 0.4–20.1 (solid)] while for AVE-B AUCnorm were comparable [1.8 ± 0.2 nM∙h (liquid),2.1 ± 0.3 nM∙h (solid)]. A pharmakcokinetic prediction model described 75% of the experimental plasma-concentration data from phase II, with good agreement (bias: -0.145 nM). Conclusions: AVAs are promising candidates as compliance biomarkers of oat intake in intervention studies regardless of the tested food matrices. However, due to their short elimination half-lives, their applicability in nutritional epidemiology where long-term habitual intake is of main interest, seems restricted. Clinical trial number: This study was registered at clinicaltrials.gov with the clinical trial number: NCT05511077, on August 22nd, 2022.
– Name: Format
  Label: File Description
  Group: SrcInfo
  Data: electronic
– Name: URL
  Label: Access URL
  Group: URL
  Data: <link linkTarget="URL" linkTerm="https://research.chalmers.se/publication/548439" linkWindow="_blank">https://research.chalmers.se/publication/548439</link><br /><link linkTarget="URL" linkTerm="https://research.chalmers.se/publication/548439/file/548439_Fulltext.pdf" linkWindow="_blank">https://research.chalmers.se/publication/548439/file/548439_Fulltext.pdf</link>
PLink https://erproxy.cvtisr.sk/sfx/access?url=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=edsswe&AN=edsswe.oai.research.chalmers.se.190230cd.9962.4b0b.84ef.8491654e18c0
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1186/s12937-025-01204-7
    Languages:
      – Text: English
    Subjects:
      – SubjectFull: Pharmacokinetic parameter
        Type: general
      – SubjectFull: Avenacosides
        Type: general
      – SubjectFull: Biomarkers of oat intake
        Type: general
      – SubjectFull: Prediction model
        Type: general
      – SubjectFull: Avenanthramides
        Type: general
    Titles:
      – TitleFull: Avenanthramides and avenacosides as biomarkers of oat intake: a pharmacokinetic study of solid and liquid oat consumption under single and repeated dose conditions
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Armeni, Marina
      – PersonEntity:
          Name:
            NameFull: Cardilin, Tim
      – PersonEntity:
          Name:
            NameFull: Fristedt, Rikard
      – PersonEntity:
          Name:
            NameFull: Karlsson, Therese
      – PersonEntity:
          Name:
            NameFull: Jenkins, Caroline Orfila
      – PersonEntity:
          Name:
            NameFull: Nordin, Elise
      – PersonEntity:
          Name:
            NameFull: Qin, Panpan
      – PersonEntity:
          Name:
            NameFull: Jirstrand, Mats
      – PersonEntity:
          Name:
            NameFull: Kristiansen, Karsten
      – PersonEntity:
          Name:
            NameFull: Savolainen, Otto
      – PersonEntity:
          Name:
            NameFull: Landberg, Rikard
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 01
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-print
              Value: 14752891
            – Type: issn-locals
              Value: SWEPUB_FREE
            – Type: issn-locals
              Value: CTH_SWEPUB
          Numbering:
            – Type: volume
              Value: 24
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Nutrition Journal
              Type: main
ResultId 1